Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Peer Review reports

Original Submission
5 Jun 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
Resubmission - Version 4
	Submitted	Manuscript version 4
5 Oct 2022	Reviewed	Reviewer Report
8 Oct 2022	Reviewed	Reviewer Report - Ilhami Yüksel
1 Nov 2022	Author responded	Author comments - Guillaume Bouguen
Resubmission - Version 5
1 Nov 2022	Submitted	Manuscript version 5
15 Nov 2022	Reviewed	Reviewer Report
Resubmission - Version 6
	Submitted	Manuscript version 6
Publishing
15 Nov 2022	Editorially accepted
1 Dec 2022	Article published	10.1186/s12876-022-02583-5

Back to article page